author-photo

Alessandra Felici

Sapienza University of Rome

84

Papers

1020

Citations

Citation Trend

Filter By

Papers (59) Sort By

Journal Conference Others

Is axitinib still a valid option for mRCC in the second-line setting? Prognostic factor analyses from the AXIS trial

2019 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (8)
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate

2017 Anti-Cancer Drugs
Show All
- Source
- Cite
- Save
Citations (4)
ABCB1, CYP3A5*3, and CYP3A4*1B SNPs and risk of toxicity with sunitinib treatment for mRCC.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Retrospective analysis of sorafenib as first or second target therapy in mRCC patients in Italian centers: An update.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

2015 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (8)
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

2015 Journal of Experimental & Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (53)
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation

2015 Future Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

2014 Future Oncology
Show All
- Source
- Cite
- Save
Citations (12)